Ultralife earnings release, August 7, 2026

Ultralife Corp (ULBI) · Form 8-K, Item 2.02 · Filed · SEC filing

Ultralife Corporation Reports Second Quarter Results

NEWARK, N.Y. – August 7, 2026 -- Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2026 with the following results:

“For the second quarter we delivered a 760-basis point improvement in gross profit margin compared to the first quarter, including the contribution of the net IEEPA refund. This improvement reflects measurable benefits realized to date from our initiatives to address manufacturing inefficiencies along with favorable sales mix. Our Communications Systems business is poised to produce revenue gains as new products move through the capture phase, and continues to expand its opportunity funnel while preparing to launch multiple new products later this year in support of government/defense programs. At the same time, we are advancing a diverse set of product development programs in our Battery & Energy Products business including programs to support water-based defense drone applications. Several of these programs are expected to transition into production later this year while we continue to execute our backlog. These multi-year revenue opportunities combined with our ongoing gross margin improvement initiatives, reinforce our outlook for profitable growth in 2026,” said Mike Manna, President and Chief Executive Officer.

Second Quarter 2026 Financial Results

Revenue was $47.9 million, a decrease of $0.6 million, or 1.3%, as compared to revenue of $48.6 million for the second quarter of 2025. Battery & Energy Products sales decreased 3.7% to $44.2 million compared to $45.9 million last year. The year-over-year decrease reflects a 4.7% decline in commercial sales due to an 8.7% decline in oil & gas and industrial sales offsetting a 7.2% increase in medical battery sales, and a 1.4% decline in government/defense sales due to the shipment of a very large order for an allied country last year. Communications Systems sales increased by 39.3% to $3.8 million compared to $2.7 million for the same period last year. Our total backlog exiting the second quarter was $117.5 million, the highest level in the Company’s history, compared to $115.1 million exiting the first quarter of 2026 and $84.5 million exiting the second quarter of 2025.

Gross profit was $13.9 million, or 28.9% of revenue, compared to $11.6 million, or 23.9% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 28.3%, compared to 23.6% last year, primarily due to favorable product mix and the refund of the IEEPA tariffs in the current period. Communications Systems gross margin was 36.3% compared to 28.4% last year, primarily due to sales mix.

Operating expenses were $10.4 million, compared to $9.3 million for the second quarter of 2025, reflecting an increase in new product development costs related to continued investment in our product offering, and one-time, non-recurring costs of $0.9 million primarily related to litigation expenses incurred for our cyber-insurance claim and the completion of certain consulting costs to help expedite our gross margin improvement. Operating expenses were 21.8% of revenue compared to 19.2% of revenue for the year-earlier period.

Operating income was $3.4 million compared to $2.3 million last year.

Other expense was $0.5 million primarily comprised of interest expense from the financing of our Electrochem acquisition partially offset by the second quarter estimated portion of a refundable tax credit for certain qualifying battery cells and packs we manufacture under the 45X Advanced Manufacturing Production Tax Credit. This compares to $1.1 million for the year-earlier period primarily reflecting the Electrochem acquisition financing and net foreign currency losses.

Net income attributable to Ultralife Corporation was $2.5 million or $0.15 per basic and diluted share on a GAAP basis, compared to $0.9 million or $0.05 per basic and diluted share for the second quarter of 2025.

Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense and one-time costs not reflective of our ongoing operations, was $6.1 million for the second quarter of 2026, or 12.8% of sales, compared to $4.1 million, or 8.5% of sales, for the year-earlier period. On a trailing twelve-month basis, adjusted EBITDA was $17.1 million or 9.1% of sales.

See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.

About Ultralife Corporation

Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.

Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.

Conference Call Information

Ultralife will hold its second quarter earnings conference call today at 8:00 AM ET.

To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: https://register-conf.media-server.com/register/BI4beea58f157a441ba44284b283b1001f... (truncated)egister and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.

Financial statements

Income Statement

Three-Month Period Ended — (Unaudited) (in thousands)

Three-Month Period Ended – June 30, – 2026Three-Month Period Ended – June 30, – 2025Six-Month Period Ended – June 30, – 2026Six-Month Period Ended – June 30, – 2025
Revenues:Battery & Energy Products44,18945,86788,34492,188
Revenues:Communications Systems3,7542,6947,0447,119
Revenues:Total Revenues47,94348,56195,38899,307
Cost of Products Sold:Battery & Energy Products31,68635,03266,48369,913
Cost of Products Sold:Communications Systems2,3911,9284,9295,048
Cost of Products Sold:Total Cost of Products Sold34,07736,96071,41274,961
Cost of Products Sold:Gross Profit13,86611,60123,97624,346
Operating Expenses:Research and Development3,2252,3186,1864,722
Operating Expenses:Selling, General and Administrative7,2047,02714,56813,969
Operating Expenses:Total Operating Expenses10,4299,34520,75418,691
Operating Expenses:Operating Income3,4372,2563,2225,655
Operating Expenses:Other Expense4511,1438992,096
Operating Expenses:Income Before Income Taxes2,9861,1132,3233,559
Operating Expenses:Income Tax Provision468243276810
Operating Expenses:Net Income2,5188702,0472,749
Operating Expenses:Net (Loss) Income Attributable to Non-Controlling Interest-25-9-455
Operating Expenses:Net Income Attributable to Ultralife Corporation2,5438792,0922,744
Operating Expenses:Net Income Per Share Attributable to Ultralife Common Shareholders – Basic0.150.050.130.17
Operating Expenses:Net Income Per Share Attributable to Ultralife Common Shareholders – Diluted0.150.050.130.17
Operating Expenses:Weighted Average Shares Outstanding – Basic16,65916,63516,65816,634
Operating Expenses:Weighted Average Shares Outstanding – Diluted16,71416,65616,70316,671

Income Statement

Three-Month Period Ended (in thousands)

Three-Month Period Ended – June 30, 2026Three-Month Period Ended – June 30, 2025Six-Month Period Ended – June 30, 2026Six-Month Period Ended – June 30, 2025
Net Income Attributable to Ultralife Corporation2,5438792,0922,744
Adjustments:Interest Expense, Net8399921,7072,024
Adjustments:Income Tax Provision468243276810
Adjustments:Depreciation Expense1,0561,0082,1101,958
Adjustments:Amortization Expense268410535815
Adjustments:Stock-Based Compensation Expense9023589462
Adjustments:Other Non-Recurring Costs8843261,731518
Adjustments:One-Time Events Impacting Production817
Adjustments:Severance Cost for Plant Closure150
Adjustments:Non-Cash Purchase Accounting Adjustment2080
Adjustments:Adjusted EBITDA6,1484,1139,3579,561

Balance Sheet

June 30, 2026 — (Unaudited) (in thousands)

June 30, 2026 – ASSETSDecember 31, 2025 – ASSETS
Current Assets:Cash6,6639,345
Current Assets:Trade Accounts Receivable, Net34,77033,948
Current Assets:Inventories, Net58,74554,008
Current Assets:Prepaid Expenses and Other Current Assets6,9808,500
Current Assets:Total Current Assets107,158105,801
Current Assets:Property, Plant and Equipment, Net39,51440,397
Current Assets:Goodwill45,36945,376
Current Assets:Other Intangible Assets, Net10,38610,933
Current Assets:Deferred Income Taxes, Net10,33510,494
Current Assets:Other Non-Current Assets3,3953,911
Current Assets:Total Assets216,157216,912
Current Liabilities:Accounts Payable22,60117,423
Current Liabilities:Current Portion of Long-Term Debt1,7504,125
Current Liabilities:Accrued Compensation and Related Benefits2,9302,754
Current Liabilities:Accrued Expenses and Other Current Liabilities10,07413,031
Current Liabilities:Total Current Liabilities37,35537,333
Current Liabilities:Long-Term Debt, Net42,85445,526
Current Liabilities:Deferred Income Taxes, Net9341,000
Current Liabilities:Other Non-Current Liabilities2,4132,919
Current Liabilities:Total Liabilities83,55686,778
Shareholders' Equity:Common Stock2,1102,109
Shareholders' Equity:Capital in Excess of Par Value192,983192,859
Shareholders' Equity:Accumulated Deficit-38,248-40,340
Shareholders' Equity:Accumulated Other Comprehensive Loss-2,846-3,141
Shareholders' Equity:Treasury Stock-21,492-21,492
Shareholders' Equity:Total Ultralife Equity132,507129,995
Shareholders' Equity:Non-Controlling Interest94139
Shareholders' Equity:Total Shareholders’ Equity132,601130,134
Shareholders' Equity:Total Liabilities and Shareholders' Equity216,157216,912
Full release

This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions including the impact of tariffs and inflation, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions, delays or material price increases in our supply of raw materials and components due to business conditions, new or additional tariffs, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife’s financial results is included in Ultralife’s Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Ultralife earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.